 · VcallConferences · Annual Reports Service |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other May 7 Calls Today's Calls |
| Call Details | |||
| Momenta Pharmaceuticals Conference Call for First Quarter 2008 Financial Results Wed, May 7, 2008, 10:00 am Eastern
| |||
| About Momenta Pharmaceuticals (NasdaqGM:MNTA) | |||
| Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Its products include M-Enoxaparin, a technology-enabled generic version of Lovenox that is used to prevent and treat deep vein thrombosis and to support the treatment of acute coronary syndromes; and M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis. The company is also developing M178 and M249, which are generic or follow-on versions of marketed therapeutic proteins. In addition, its products comprise M118, a low molecular weight heparin that is in Phase I clinical trial to support the treatment of patients diagnosed with ACS and stable angina; and glycoprotein drugs. Momenta Pharmaceuticals has collaborations with Sandoz N.V. and Sandoz, Inc. to develop and commercialize injectable enoxaparin. The company was founded in 2001. It was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in 2002. Momenta Pharmaceuticals is based in Cambridge, Massachusetts. | |||
More Info: | |||
